PMID- 34375127
OWN - NLM
STAT- MEDLINE
DCOM- 20211231
LR  - 20211231
IS  - 1557-900X (Electronic)
IS  - 0892-7790 (Linking)
VI  - 35
IP  - 12
DP  - 2021 Dec
TI  - Single-Use Digital Flexible Ureteroscopes as a Safe and Effective Choice for the 
      Treatment of Lower Pole Renal Stones: Secondary Analysis of a 
      Randomized-Controlled Trial.
PG  - 1773-1778
LID - 10.1089/end.2021.0170 [doi]
AB  - Objective: To compare the efficacy and safety of a single-use digital flexible 
      ureteroscope (FURS) and a reusable FURS for the treatment of lower pole stones 
      (LPS) smaller than 20 mm. Patients and Methods: We analyzed the data of 49 
      patients with LPS from our previous multicenter, randomized, open-label clinical 
      trial in four hospitals in China. All patients underwent FURS for LPS with a 
      single-use FURS ZebraScope (trial group) or a reusable FURS URF-V (control 
      group). The efficacy endpoints assessed were the 1-month postsurgical stone-free 
      rate (SFR), operative time, length of postoperative hospital stay, and mean 
      reduction in hemoglobin level. The safety outcomes assessed were the presence of 
      adverse events (AEs), severe AEs (SAEs), and postoperative complications. 
      Results: The demographic and preoperative parameters were comparable between the 
      two groups. The 1-month SFR was 84.00% for the ZebraScope group and 58.33% for 
      the reusable flexible ureteroscope (URF-V) group (p < 0.05). There was no 
      difference between the two groups in the operative time (p = 0.665), length of 
      hospital stay (p = 0.308), presence of postoperative complications (p = 0.307), 
      presence of AEs (p = 0.483), and the presence of SAEs (p = 0.141). Conclusions: 
      This study demonstrates that single-use digital FURS is a safe and effective 
      option and can offer higher SFR than the reusable FURS in the treatment of LPS 
      smaller than 20 mm. We recommend single-use digital FURS as an alternative to 
      reusable FURS for the treatment of LPS. The Clinical Trial Registration number: 
      ChiCTR1900021615.
FAU - Yang, Enguang
AU  - Yang E
AD  - Institute of Urology, Lanzhou University Second Hospital, Key Laboratory of Gansu 
      Province for Urological Diseases, Gansu Nephro-Urological Clinical Center, 
      Lanzhou, China.
FAU - Jing, Suoshi
AU  - Jing S
AD  - Department of Urology, The First Hospital of Lanzhou University, Lanzhou, China.
FAU - Niu, Yuanjie
AU  - Niu Y
AD  - Department of Urology, Tianjin Institute of Urology, The Second Hospital of 
      Tianjin Medical University, Tianjin, China.
FAU - Qi, Shiyong
AU  - Qi S
AD  - Department of Urology, Tianjin Institute of Urology, The Second Hospital of 
      Tianjin Medical University, Tianjin, China.
FAU - Yadav, Prabin Kumar
AU  - Yadav PK
AD  - Institute of Urology, Lanzhou University Second Hospital, Key Laboratory of Gansu 
      Province for Urological Diseases, Gansu Nephro-Urological Clinical Center, 
      Lanzhou, China.
FAU - Yang, Li
AU  - Yang L
AD  - Institute of Urology, Lanzhou University Second Hospital, Key Laboratory of Gansu 
      Province for Urological Diseases, Gansu Nephro-Urological Clinical Center, 
      Lanzhou, China.
FAU - Bao, Junsheng
AU  - Bao J
AD  - Institute of Urology, Lanzhou University Second Hospital, Key Laboratory of Gansu 
      Province for Urological Diseases, Gansu Nephro-Urological Clinical Center, 
      Lanzhou, China.
FAU - Tian, Junqiang
AU  - Tian J
AD  - Institute of Urology, Lanzhou University Second Hospital, Key Laboratory of Gansu 
      Province for Urological Diseases, Gansu Nephro-Urological Clinical Center, 
      Lanzhou, China.
FAU - Wang, Juan
AU  - Wang J
AD  - Institute of Urology, Lanzhou University Second Hospital, Key Laboratory of Gansu 
      Province for Urological Diseases, Gansu Nephro-Urological Clinical Center, 
      Lanzhou, China.
FAU - Li, Ningchen
AU  - Li N
AD  - Department of Urology, Peking University Shougang Hospital, Beijing, China.
FAU - Ou, Tongwen
AU  - Ou T
AD  - Department of Urology, Beijing Xuanwu Hospital, Capital Medical University, 
      Beijing, China.
FAU - Wang, Zhiping
AU  - Wang Z
AD  - Institute of Urology, Lanzhou University Second Hospital, Key Laboratory of Gansu 
      Province for Urological Diseases, Gansu Nephro-Urological Clinical Center, 
      Lanzhou, China.
LA  - eng
SI  - ChiCTR/ChiCTR1900021615
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Endourol
JT  - Journal of endourology
JID - 8807503
SB  - IM
MH  - Humans
MH  - *Kidney Calculi/surgery
MH  - *Lithotripsy, Laser
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Ureteroscopes
MH  - Ureteroscopy/adverse effects
OTO - NOTNLM
OT  - efficiency
OT  - lower pole
OT  - randomized-controlled trial
OT  - renal calculi
OT  - ureteroscopy
EDAT- 2021/08/11 06:00
MHDA- 2022/01/01 06:00
CRDT- 2021/08/10 17:11
PHST- 2021/08/11 06:00 [pubmed]
PHST- 2022/01/01 06:00 [medline]
PHST- 2021/08/10 17:11 [entrez]
AID - 10.1089/end.2021.0170 [doi]
PST - ppublish
SO  - J Endourol. 2021 Dec;35(12):1773-1778. doi: 10.1089/end.2021.0170.